FDG-PET to Evaluate Response to Hyperthermic Isolated Limb Perfusion for Locally Advanced Soft-Tissue Sarcoma

Journal of Nuclear Medicine

Volumn 37, Issue 6, 1996, Pages 984-990

  Van Ginkel, Robert J ^b   Hoekstra, Harald J ^a   Pruim, Jan ^b   Nieweg, Omgo E ^b   Molenaar, Willemina M ^b   Paans, Anne M J ^b   Willemsen, Antoon T M ^b   Vaalburg, Willem ^b   Koops, Heimen Schraffordt ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

Fluorine 18 fluorodeoxyglucose; Hyperthermic isolated limb perfusion; PET; Sarcoma; Tumor necrosis factor

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYGLUCOSE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; FLUORODEOXYGLUCOSE F 18; GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; HYPERTHERMIC THERAPY; LIMB; MALE; MIDDLE AGED; REGIONAL PERFUSION; SARCOMA; SCINTISCANNING; SOFT TISSUE TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DEOXYGLUCOSE; EXTREMITIES; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; HYPERTHERMIA, INDUCED; INTERFERON TYPE II; MALE; MELPHALAN; MIDDLE AGED; SARCOMA; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030161484     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Mazanet R, Antman KH. Sarcomas of soft tissue and bone. Cancer 1991;68:463-473.
2. Suit HD. Local control and patient survival. Int J Radiat Oncol Biol Phys 1992;23:653-660.
3. Sadoski C, Suit HD, Rosenberg A, Mankin H, Efird J. Preoperative radiation, surgical margins and local control of extremity sarcomas of soft tissues. J Surg Oncol 1993;52:223-230.
4. Hoekstra HJ, Schraffordt Koops H, Molenaar WM, et al. A combination of intraarterial chemotherapy, preoperative and postoperative radiotherapy and surgery as limb-saving treatment of primarily unresectable high-grade soft tissue sarcomas of the extremities. Cancer 1989;63:59-62.
5. Eilber F, Eckardt J, Rosen G, Forscher C, Selch M. Improved complete response rate with neoadjuvant chemotherapy and radiation for high grade extremity soft-tissue sarcoma. Proc Am Soc Clin Oncol 1994;13:473.
6. Hoekstra HJ, Schraffordt Koops H, Molenaar WM, Oldhoff J. Results of isolated regional perfusion in the treatment of malignant soft-tissue tumors of the extremities. Cancer 1987;60:1703-1707.
7. Lehti PM, Moseley HS, Janoff K, Stevens K, Fletcher WS. Improved survival for soft-tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet 1986;162:149-152.
8. Meyer M, Muchmore JH, Krementz ET. Pre- and perioperative perfusion chemotherapy for soft-tissue sarcoma of the limbs. Cancer Treat Res 1991;56:105-126.
9. Guchelaar HJ, Hoekstra HJ, De Vries EGE, Uges DR, Oosterhuis JW, Schraffordt Koops H. Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumors of the extremities. Br J Cancer 1992;65:898-902.
10. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interteron gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
11. Eggermont AMM, Lienard D, Schraffordt Koops H, Rosenkaimer F, Lejeune FJ. Treatment of irresectable soft-tissue sarcomas of the limbs by isolation perfusion with high dose TNFalfa in combination with interferon-gamma and melphalan. In: Fiers W, Buurman WA, eds. Tumor necrosis factor molecular and cellular biology and clinical relevance, 1st ed. Basel: Karger; 1993:239-243.
12. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-648.
13. Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988;29:181-186.
14. Warburg O. On the origin of cancer cells. Science 1956;123:309-314.
15. Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992;182:185-194.
16. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET J Nucl Med 1991;32:1508-1512.
17. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37:257-261.
18. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18-fluorodeoxyglucose. J Nucl Med 1988;29:1521-1525.
19. Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991;32:1655-1660.
20. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-2111.
21. Enzinger FM, Weiss SW. Soft-tissue tumors. St Louis: Mosby; 1988.
22. Coindre JM, Trojani M, Contesso G, et al. Reproducibility of a histopathologic grading system for adult soft-tissue sarcoma. Cancer 1986;58:306-309.
23. Creech O, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616-632.
24. Fontijne WP, Mook PH, Schraffordt Koops H, Oldhoff J, Wildevuur CR. Improved tissue perfusion during pressure regulated regional perfusion: a clinical study. Cancer 1985;55:1455-1461.
25. Wieberdink J, Benckhuysen C, Braat RP, Van Slooten EA, Olthuis GAA. Dosimetry in isolation perfusion of the limb by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-910.
26. Schraffordt Koops H. Prevention of neural and muscular lesions during hyperthermic regional perfusion. Surg Gynecol Obstet 1972;135:401-403.
27. 18mF-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-238.
28. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
29. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-590.
30. Winer BJ. Statistical principles in experimental design. New York: McGraw Hill; 1971.
31. Nawroth P, Handley D, Matsueda G, de Waal R, Gerlach H, Blohm DSD. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med 1988;168:637-647.
32. 18F-FDG PET [Abstract]. J Nucl Med 1994;35(suppl):38P.
33. 18F]fluorodeoxyglucose uptake in abdominal abscesses: a PET study. J Comput Assist Tomogr 1989;13:829-831.
34. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of lluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-1980.
35. Palladino MA Jr, Shalaby MR, Kramer SM, et al. Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol 1987;138:4023-4032.
36. Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 1985;82:8667-8671.
37. Renard N, Lienard D, Lespagnard E, Eggermont AMM, Heimann R, Lejeune FJ. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumor necrosis factor alpha (rTNFα). Int J Cancer 1994;57:656-663.
38. Nieweg OE, Wong WH, Singletary SE, Hortobagyi GN, Kim EE. Positron emission tomography of glucose metabolism in breast cancer. Potential for tumor detection, staging and evaluation of chemotherapy. Ann NY Acad Sci 1993;698:423-428.
39. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993;34:12-17.
40. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485-1490.
41. Strauss LG, Dimitrakopoulou A, Haberkorn U, Ostertag H, Helus F, Lorenz WJ. PET studies with FDG in patients with metastatic melanoma prior and after therapy. Eur J Nucl Med 1991;18:685.
42. 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: preliminary study of lung cancer. Int J Radiat Oncol Biol Phys 1990;19:1005-1010.
43. Bares R, Horstmann K, Altehoefer C, et al. FDG-PET 10 assess local effects of radiation or chemotherapy in patients with malignant lymphoma [Abstract]. J Nucl Med 1991;32(suppl):918P.
44. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.